Ibrutinib and Nivolumab in Treating Participants With Metastatic Solid Tumors

Metastatic Malignant Solid Neoplasm Clinical Trial

Official title:

Pilot Study Testing the Effects of BTK Inhibitor Ibrutinib on Levels and Function of Myeloid Derived Suppressor Cells and Other Immune Subsets in Patients With Metastatic Solid Tumors

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03525925
• Other study ID #: OSU-18015
• Secondary ID: NCI-2018-00423
• Status: Completed
• Phase: Phase 1
• Start date: July 18, 2018
• Est. completion date: July 31, 2022

Study information

• Verified date: March 2024
• Source: Ohio State University Comprehensive Cancer Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This phase I trial studies how well ibrutinib and nivolumab work in treating participants with solid tumors that have spread to other places in the body. Ibrutinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as nivolumab, may interfere with the ability of tumor cells to grow and spread. Giving ibrutinib and nivolumab may work better in treating participants with solid tumors.

Description:

PRIMARY OBJECTIVES:

I. Evaluate the effect of the ibrutinib therapy on circulating levels of myeloid derived suppressor cells MDSC.

SECONDARY OBJECTIVES:

I. Assess safety of the study combination in study subjects.

EXPLORATORY OBJECTIVES:

I. Evaluate the effect of the ibrutinib/nivolumab therapy on circulating levels of MDSC.

II. Evaluate the effect of the ibrutinib and ibrutinib/nivolumab therapy on the immunosuppressive function of circulating MDSC by measuring their ability to inhibit T cell proliferation and natural killer cell mediated antibody dependent cell cytotoxicity.

III. Study the effect of ibrutinib and ibrutinib/nivolumab therapy on levels of circulating innate and adaptive immune cells such as natural killer cell and T lymphocyte subsets.

IV. Study circulating MDSC levels at the time of disease progression. V. Evaluate in a preliminary fashion the effect of the regimen on progression-free survival.

OUTLINE:

Participants receive ibrutinib orally (PO) daily for 15 days. After 7 days receiving ibrutinib, participants receive nivolumab intravenously (IV) over 60 minutes on days 1 and

15. Courses with nivolumab repeat every 28 days in the absence of disease progression or unaccepted toxicity.

After completion of study treatment, participants are followed up every 3 months.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 16
• Est. completion date: July 31, 2022
• Est. primary completion date: February 20, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Patients with biopsy-proven metastatic solid tumor and be eligible to receive nivolumab per standard of care

• Patients will be allowed to have any number of prior lines of therapy for metastatic cancer

• Patients with measurable and non-measurable disease are allowed to participate

• Absolute neutrophil count (ANC) ? 1.5 x 10^3/mm^3

• Hemoglobin (Hgb) ? 9 g/dL

• Platelet count ? 100 x10^3/mm^3

• Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ? 2.5 x upper limit of normal (ULN) or ? 5 x ULN in patients with liver metastases

• Prothrombin time ? 1.5 x ULN

• Total bilirubin ? 1.5 x ULN (unconjugated bilirubin of < 3 x ULN for patients with known Gilbert syndrome)

• Creatinine clearance of ? 50 ml/min by Cockcroft-Gault equation

• Corrected QT interval of < 480 msec (using either Bazett?s or Fridericia's formula)

• Life expectancy of > 12 weeks

• Eastern Cooperative Oncology Group (ECOG) performance status 0 ? 2

• Sexually active women with child bearing potential must have a negative pregnancy test obtained within 14 days prior to initiating study treatment

• Sexually active women of child-bearing potential and men must agree to use adequate contraception prior to study entry, for the duration of study participation and for 3 months after completion of study treatment administration; adequate contraception includes methods such as oral contraceptives, double barrier method (condom plus spermicide or diaphragm), or abstaining from sexual intercourse

Exclusion Criteria:

• History of prior therapy with ibrutinib or nivolumab

• Unable to swallow capsules or having disease that is significantly affecting gastrointestinal function and/or inhibiting small intestine absorption

• Diagnosis of congenital or acquired immunodeficiency with the exception of chemotherapy induced immune suppression

• Active autoimmune disease requiring systemic treatment within the past 3 months or a documented history of clinically severe autoimmune disease, or a syndrome that requires systemic steroids of greater than or equal to prednisone 10 mg/day or other immunosuppressive agents; patients with history of adequately treated Hashimoto?s thyroiditis will be eligible; patients requiring a short course of a high dose prednisone burst to treat asthma or common obstructive pulmonary disease will also be eligible 5 days following completion of the prednisone treatment

• Use of systemic steroids at a dose above 10 mg/day of prednisone or prednisone equivalent in cycle 1 of study therapy; systemic steroids must be discontinued at least 5 days prior to initiating study therapy; exception will be given to patients who develop immune related adverse events that necessitate use of steroids or other immune suppressive agents; following cycle 1 of study treatment, the use of systemic steroids will be allowed per discretion of the treating physician

• Active, non-infectious pneumonitis

• Ongoing or active infection requiring systemic therapy

• History of being positive for human immunodeficiency virus (HIV)

• History of hepatitis B or C

• History of receiving live vaccine within 30 days of planned start of study therapy

• Central nervous system (CNS) metastases or leptomeningeal carcinomatosis; patients with history of adequately treated brain metastases that are stable for > 2 weeks prior to the first dose of study regimen are eligible as long they no longer require steroids and have no seizures or worsening focal neurologic symptoms; anti-epileptic therapy will be allowed

• Patients who had prior systemic chemotherapy within 3 weeks (or < 5 half-lives ? whichever is longer)

• Prior radiation therapy within 2 weeks of study enrollment

• Prior investigational therapy within 4 weeks

• Major surgery within 4 weeks or minor surgery within 2 weeks prior to the first dose of study drug; port placement will not be considered major or minor surgery

• Any inter-current, uncontrolled systemic illness or any medical or psychiatric condition that in the opinion of the investigator would make the study therapy unsafe to the patient

• Unable to understand and sign informed consent form

• Uncontrolled, active cardiovascular disease including, but not limited to: symptomatic congestive heart failure, any class 3 or 4 cardiac disease as defined by the New York Heart Association functional classification, unstable angina pectoris, cardiac arrhythmia

• Any medications or substances that are strong inhibitors or inducers of CYP 3A4 need to be discontinued prior to initiation the study therapy and for the duration of ibrutinib treatment; patients can resume these medications 3 days after completion of ibrutinib course

• History of allergic reactions attributed to compounds of similar chemical or biologic composition as ibrutinib or nivolumab

Related Conditions & MeSH terms

• Metastatic Malignant Solid Neoplasm

Intervention

Drug:
• Ibrutinib
Given PO

Other:
• Laboratory Biomarker Analysis
Correlative studies

Biological:
• Nivolumab
Given IV

Locations

Country	Name	City	State
United States	Ohio State University Comprehensive Cancer Center	Columbus	Ohio

Sponsors (1)

Lead Sponsor	Collaborator
Ohio State University Comprehensive Cancer Center

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Biomarker analysis	Will assess the association between the clinical responses and biomarkers/immune cell populations of interest will be identified using conventional techniques. These analyses will be primarily exploratory and hypothesis-generating. Will study the biomarker association with clinical outcomes using descriptive statistics, graphical methods and statistical modeling where appropriate. T-tests (continuous variables), chi-square or Fisher?s Exact tests (categorical variables), logistic regression models or Cox proportional hazard models will be used to explore associations between biomarkers/immune cell populations and clinical responses, whichever is appropriate. Pre and post treatment biomarkers will be compared using either paired t-tests or non-parametric tests if necessary.	Up to 2 years
Primary	Circulating levels of myeloid derived suppressor cells	Will be summarized using descriptive statistics (N, mean, standard deviation, median, minimum, and maximum) and/or frequency and percentages for medically relevant categories. Changes of the continuous variables will be estimated using mixed model for repeated measures with proper data transformation as needed, and two-way tables and Chi-Square test will be used to summarize the changes of the categorical data.	Up to 2 years
Secondary	Incidence of adverse events	Will be assessed by National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0. Will be presented using frequencies and percentages.	Up to 2 years
Secondary	Progression free survival	One year progression free survival will be defined as proportion of patients who are free of disease progression or death (whichever occurs first) after 1 year of follow up. Progression free survival will be summarized using Kaplan and Meier methods, where patients who are event-free at the time of their last evaluation will be censored at that time point.	Interval from study enrollment to first documented disease progression according to Response Evaluation Criteria in Solid Tumors 1.1 or death from any cause (whichever occurs first), assessed at 1 year

External Links

•   The Jamesline